Hemodynamic profile of pulmonary arterial hypertension in a Tunisian center


Amira Jamoussi
Nacef Ben Mrad
Emna Rachdi
Fatma Jarraya
Sarra Zairi
Kais Ben Romdhane
Mohamed Besbes
Samia Ayed
Jalila Ben Khelil


Introduction: Pulmonary hypertension (PH) management can only be conceived in a specialized center. We aimed to report the experience of a Tunisian ICU about PH invasive hemodynamic exploration and to describe consequent therapeutic decisions.

Methods: Retrospective descriptive study including all patients admitted to the medical ICU of Abderrahmen Mami Hospital for right heart catheterization (RHC), between 2005 and 2019 as part of the investigation of PH. Patients’ characteristics, procedure safety and arising therapeutic decisions were then reported.

Results: Forty patients were admitted for hemodynamic evaluation. RHC confirmed PH in 31 patients and exploration was then completed with NO reactivity test. Mean age was 41.3±15 years, gender ratio M/F was 1.06. PH was classified into: group 1 (n=13), group 2 (n=14), group 4 (n=2) and group 5 (n=2). NO vasoreactivity test was positive in 50% of post-capillary PH and in 28% of pre-capillary PH. The therapeutic decision following the reversibility test was: prescription of calcium channel blockers (n=5), a specific pulmonary vasodilator (n=10), operability (n=6), heart-lung transplant (n=3) and therapeutic abstention (n=7). Two minor complications were reported.

Conclusion: The medical ICU in Abderrahmen Mami Hospital represents an experienced team in hemodynamic investigations despite low annual RHC number. NO reactivity test is an indispensable tool that enables important decisions during PH management.


Pulmonary hypertension, right heart catheterization, vasoreactivity test , referral center, ICU



  1. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4:306-22.
  2. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119.
  3. Ben Abdelaziz A, Ben Hassine D, Chebil D, Nouira S, Ben Abdelaziz A, Melki S, Barhoumi T, Ben Salem K. Descriptive Statistics in Health Sciences. Tunis Med. 2021 DéCembre;99(12):1117-1125. English. PMID: 35288917; PMCID: PMC8974418.
  4. Elshazly M, Mostafa AI, Ibrahim A, Sabry IM. Assessing the spectrum of pulmonary hypertension identified at an Egyptian expert referral center. Egypt J Bronchol. 2021;15:48.
  5. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM, Capener D, et al. ASPIRE registry: Assessing the spectrum of pulmonary hypertension identified at a referral centre. Eur Respir J. 2012;39:945-55.
  6. Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017;36:957-67.
  7. D'Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues. Heart Fail Clin. 2018;14:467-77.
  8. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48:2546-52.
  9. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology. Recommendations on the management of pulmonary hypertension in clinical practice. Heart. 2001;86(Suppl1):I1-I13.
  10. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax. 2008;63(Suppl2):ii1-ii41.
  11. Barberà JA, Escribano P, Morales P, Gómez MA, Oribe M, Martínez A, et al. Sociedad Española de Neumología y Cirugía Torácica; Sociedad Española de Cardiología. Estándares asistenciales en hipertensión pulmonar. Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC) [Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)]. Rev Esp Cardiol. 2008;61:170-84. [Spanish].
  12. Armstrong I, Rochnia N, Harries C, Bundock S, Yorke J. The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study. BMJ Open. 2012;2:e000806.
  13. Ghofrani HA, Distler O, Gerhardt F, Gorenflo M, Grünig E, Haefeli WE, et al. Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011;154(Suppl1):S20-S33.
  14. Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev. 2012;21:313-20.